Amanda Winters, MD, PhD

Assistant Professor, Pediatrics

I am a Pediatric Oncologist at Children’s Hospital Colorado and am junior faculty in the Jordan lab. My project involves the characterization of chemo-resistant cell populations in acute myeloid leukemias (AML), with the ultimate goal of identifying effective targeted therapies for residual disease. An additional goal of my research is to develop more sensitive and specific assays for the detection of minimal residual disease (MRD) in patients with no clinically apparent disease.

Currently, I am working with adult and pediatric primary AML samples, which I am analyzing with mass cytometry and with targeted sequencing of a panel of AML-associated genes.  Mass cytometry allows us to look at >20 cell surface markers and intracellular phosphorylated signaling proteins simultaneously, which in turn allows us to identify individual subpopulations within an AML sample and track their relative abundances during initial chemotherapy. We can then isolate the subpopulations which are most resistant to standard chemotherapies and can study their genetic mutational profiles and sensitivities to targeted drug therapies. We can also use the genotypic information to identify candidate mutations for MRD monitoring via droplet digital PCR, with the goal of detecting molecular evidence of disease at earlier timepoints prior to clinical relapse.

Picture of Amanda Winters

Picture of Researcher Holding Up Slide

Haobin Ye, PhD

Postdoctoral Fellow

My research focused on the interaction between leukemia cells and their microenvironment, especially the ones created by the adipose tissue. 

I am interested in how the microenvironment provided by the adipose tissue affects the metabolism and survival of leukemia cells and how leukemia cells change the biological behavior of the adipose tissue.